CD38 and Miyoshi myopathy: Lastly, at the time of this manuscript, carfilzomib is not reimbursed in combination with anti‐CD38 MAbs, though they have received regulatory approvals, which is an important component of modern MM therapy and will require follow‐up in the future to evaluate those outcomes.